Increased levels of PD-1 and PD-L1 expression on tumor-infiltrating immune cells as compared to homologous recombination proficient tumors indicates that PD-1/PD-L1 inhibitors may be more effective in BRCA1/2-mutated rather than in the homologous recombination proficient HGSOC [75]. Here, BRCA1 is linked to neoplasm.